triazoles has been researched along with ribociclib in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bardia, A; Beck, JT; Conte, P; Curigliano, G; Dhuria, S; Di Tomaso, E; Gómez Pardo, P; Hurvitz, SA; Lolkema, MP; Martínez García, M; Meric-Bernstam, F; Miller, M; Penault-Llorca, F; Solovieff, N; Tang, Z | 1 |
Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D | 1 |
Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
Messina, C; Messina, M; Zanardi, E | 1 |
Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E | 1 |
Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
2 review(s) available for triazoles and ribociclib
Article | Year |
---|---|
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
3 trial(s) available for triazoles and ribociclib
Article | Year |
---|---|
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; Cyclin D3; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Oncogene Proteins; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Signal Transduction; Triazoles | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2016 |
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
2 other study(ies) available for triazoles and ribociclib
Article | Year |
---|---|
Ribociclib Lengthens Breast Cancer Survival.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Purines; Treatment Outcome; Triazoles | 2016 |
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Models, Biological; Models, Economic; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles; United States | 2018 |